Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus S-1 vs anlotinib alone in third- or later-line stage IV NSCLC (real-world study)
ChiCTR2200064871Phase 2Not yet recruiting
- Sponsor
- Mianyang Central Hospital
- Start
- Oct 2022
- Modality
- Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib and tegafur + gimeracil + oteracil in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mianyang Central Hospital. Primary endpoints: Complete response rate, Partial response rate and 4 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
anlotinibtegafur + gimeracil + oteracil
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200064871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064871.